Golin Health has won two new accounts, having been selected by HRA Pharma and Atlantis Healthcare as they look to communicate and promote their respective brands.
For HRA Pharma Golin will be working to raise awareness of the French company's emergency contraceptive pill ellaOne (ulipristal acetate) in the UK, targeting both pharmacists and women of childbearing age.
EllaOne was granted EU-wide approval by the European commission's advisory authority in May 2009 and is now available as an over the counter medicine in all member states, except Hungary.
Tony Fraser, general manager of HRA Pharma, said: “PR will be the key gate keeper to all communication across both trade and consumer so getting it right here is key.”
Golin Health will create an insight-driven education programme to “dispel preconceived ideas around emergency contraception” and so combat what it calls “judgement barriers” as a part of a multichannel communications drive to raise awareness about HRA Pharma's morning after pill.
Meanwhile, the London-based agency has also been brought in by Atlantis Healthcare to run targeted marketing initiatives and press office support.
Atlantis Healthcare specialises in the development and execution of treatment adherence programmes for pharmaceutical companies across the globe with a focus on the role of psychology in patient outcomes.
Managing director of Atlantis Healthcare UK Jonny Duder said: “We are looking forward to implementing the communications plan … to build awareness in both the issue of poor patient adherence and self-management and our solutions to address these significant problems.”
Golin Health opened its London office in 2013 and was a finalist in the excellence in digital communications category at last year's Communiqué Awards with its Rosacea Uncovered educational campaign for Omega Pharma.